Pfizer has a plan to bounce back from recent obstacles.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
20don MSN
Pfizer stock: Buy, sell, or hold?
The company is entering what could be a particularly challenging period.
Pfizer's $7.7B cost-savings plan is boosting margins and EPS, offsetting COVID revenue declines and patent cliff concerns. Core business is growing 12% ex-COVID, with strength in oncology, vaccines, ...
Pfizer raised the midpoint of its full-year 2026 revenue guidance by $500 million after stronger-than-expected performance from its non-COVID portfolio offset a reduction in anticipated Comirnaty and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pfizer has been going through a period of transition.
Pfizer offers a 7% dividend yield, providing steady income despite stagnant share performance in recent months. COVID-19 product sales have sharply declined, with Paxlovid down 55% and vaccine revenue ...
Pfizer’s PFE fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results